Appendix B: Panel Roster and Financial Disclosures
Invasive Mycoses
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| John Baddley | University of Maryland School of Medicine | Synexis | Research Support (paid to institution) |
| David Boulware | University of Minnesota Medical School |
Appili Therapeutics Matinas BioPharma |
Research Support (paid to institution) |
| Marisa Miceli | University of Michigan Medical School |
SCYNEXIS F2G Mayne Pharma |
Research Support (paid to institution) |
| SCYNEXIS | Data Safety Monitoring Board | ||
| Astellas Pharma | Consulting | ||
| John Perfect* | Duke University, School of Medicine | Pfizer | Scientific Advisory Board |
| George R. Thompson | University of California, Davis Medical Center |
Amplyx Pharmaceuticals Astellas Pharm Cidara Therapeutics F2G Mayne Pharma |
Scientific Advisory Board |
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. |
|||
Download Guidelines
- Section Only PDF (31.04 KB)
- Full Guideline PDF (5.8 MB)
- Tables Only PDF (1006.96 KB)